472 related articles for article (PubMed ID: 27858509)
1. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
Thommes EW; Kruse M; Kohli M; Sharma R; Noorduyn SG
Hum Vaccin Immunother; 2017 Apr; 13(4):867-876. PubMed ID: 27858509
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
4. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B.
McKeage K
Drugs; 2013 Sep; 73(14):1587-94. PubMed ID: 24022123
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
Nagy L; Heikkinen T; Sackeyfio A; Pitman R
Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
Yang MC; Tan EC; Su JJ
Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the health economic consequences of quadrivalent influenza vaccination.
de Boer PT; van Maanen BM; Damm O; Ultsch B; Dolk FCK; Crépey P; Pitman R; Wilschut JC; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):249-265. PubMed ID: 28613092
[TBL] [Abstract][Full Text] [Related]
14. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
Hendriks J; Hutubessy RCW; Grohmann G; Torelli G; Friede M; Kieny MP
Vaccine; 2018 Jun; 36(28):3993-3997. PubMed ID: 29866617
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
[TBL] [Abstract][Full Text] [Related]
19. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
Uhart M; Bricout H; Clay E; Largeron N
Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
[TBL] [Abstract][Full Text] [Related]
20. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
